NCT02920801View on ClinicalTrials.gov

Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

saxagliptin

5mg per day for 12 weeks

DRUG

Metformin

1500mg per day for 12 weeks

Trial Locations (1)

200032

Fang Li, Shanghai

All Listed Sponsors
collaborator

Chinese Medical Association

NETWORK

lead

Shanghai Zhongshan Hospital

OTHER

NCT02920801 - Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter